Overview

A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects

Status:
Completed
Trial end date:
2017-01-25
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the effects of hepatic impairment on the pharmacokinetics (PK) of E2609 after a single dose administration.
Phase:
Phase 1
Details
Lead Sponsor:
Eisai Inc.